245 related articles for article (PubMed ID: 16960243)
1. Medical therapy: where are we now?
Resman-Targoff BH
Am J Health Syst Pharm; 2006 Sep; 63(18 Suppl 4):S11-8. PubMed ID: 16960243
[TBL] [Abstract][Full Text] [Related]
2. Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
Kremer JM
Ann Intern Med; 2001 Apr; 134(8):695-706. PubMed ID: 11304108
[TBL] [Abstract][Full Text] [Related]
3. [2 years data of controlled trials with leflunomide vs. methotrexate and leflunomide vs. sulfasalazine].
Krüger K
Z Rheumatol; 2002 Jun; 61(3):308-10. PubMed ID: 12219638
[No Abstract] [Full Text] [Related]
4. Leflunomide in the treatment of rheumatoid arthritis.
Li EK; Tam LS; Tomlinson B
Clin Ther; 2004 Apr; 26(4):447-59. PubMed ID: 15189743
[TBL] [Abstract][Full Text] [Related]
5. Advances in the medical management of rheumatoid arthritis.
Scott DL
Hosp Med; 2002 May; 63(5):294-7. PubMed ID: 12066349
[TBL] [Abstract][Full Text] [Related]
6. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
7. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
O'Dell JR
Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S53-8. PubMed ID: 10589358
[TBL] [Abstract][Full Text] [Related]
8. Disease modification in rheumatoid arthritis with leflunomide.
Emery P
Scand J Rheumatol Suppl; 1999; 112():9-14. PubMed ID: 10668522
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
[TBL] [Abstract][Full Text] [Related]
10. Therapies for active rheumatoid arthritis after methotrexate failure.
O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
[TBL] [Abstract][Full Text] [Related]
11. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
Scott DL; Strand V
Rheumatology (Oxford); 2002 Aug; 41(8):899-909. PubMed ID: 12154207
[TBL] [Abstract][Full Text] [Related]
12. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
Sizova L
Br J Clin Pharmacol; 2008 Aug; 66(2):173-8. PubMed ID: 18537958
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
[TBL] [Abstract][Full Text] [Related]
14. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials.
Golicki D; Newada M; Lis J; Pol K; Hermanowski T; Tłustochowicz M
Pol Arch Med Wewn; 2012; 122(1-2):22-32. PubMed ID: 22353705
[TBL] [Abstract][Full Text] [Related]
16. Challenges and treatment options for rheumatoid arthritis during pregnancy.
Gerosa M; Schioppo T; Meroni PL
Expert Opin Pharmacother; 2016 Aug; 17(11):1539-47. PubMed ID: 27283340
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
18. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
Schoels M; Kapral T; Stamm T; Smolen JS; Aletaha D
Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
[TBL] [Abstract][Full Text] [Related]
19. Leflunomide and rheumatoid arthritis: new preparation. Neither the safest nor the most effective slow-acting antirheumatic drug.
Prescrire Int; 2001 Apr; 10(52):36-9. PubMed ID: 11718154
[TBL] [Abstract][Full Text] [Related]
20. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis.
Rodriguez-Rodriguez L; Jover-Jover JA; Fontsere O; Peña-Blanco RC; León L; Fernández-Gutierrez B; Abásolo L
Scand J Rheumatol; 2013; 42(6):433-6. PubMed ID: 23742043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
